Beauty brands are retooling how they build and substantiate product claims, as artificial intelligence becomes a primary gatekeeper between products and consumers. That is the core finding of a new BeautyMatter analysis, "How Beauty Brands Are Building Evidence-Based Claims for the AI Era," which examines the shift from marketing-led positioning toward data-backed, verifiable claims that algorithms can parse, rank, and repeat.

The stakes are practical. When a consumer asks a chatbot or AI-assistant for the best serum for a specific concern, the answer draws on structured, citable evidence rather than ad copy. Brands whose claims rest on clinical data, published studies, and clearly labeled ingredient information are the ones machine systems can surface accurately. Vague superlatives, by contrast, do not survive translation into an algorithmic recommendation.

Why does substantiation matter more now?

The BeautyMatter report frames the change as an extension of an existing regulatory direction rather than a break from it. Regulators in major markets have pressed the industry toward claim substantiation for years, and AI effectively enforces the same discipline at the speed of a search query.

For formulators and regulatory teams, the implications run along three lines:

• Claim architecture. Assertions must trace to specific evidence — study results, ingredient data, or consumer testing — rather than aspirational language.
• Data structure. Evidence needs to live in formats that AI systems can read and attribute, from structured product pages to published trial data.
• Consistency. A claim repeated by an AI assistant amplifies any weakness in its substantiation, so sloppy claims now carry a distribution penalty, not just a compliance risk.

The takeaway for product teams: substantiation has moved from a back-office compliance task to a front-end commercial asset.

What changes for product development?

According to the BeautyMatter analysis, brands are responding by embedding evidence generation earlier in the development cycle. Clinical and consumer testing programs are being designed with the final claim language in mind, so that the data collected maps directly onto what marketing and AI-visible channels will say about the finished product.

That sequencing matters. A brand that decides its claim strategy after formulation completes often discovers the data it holds cannot support the language it wants. Building the claim into the test design from the start closes that gap.

For procurement and R&D, this means suppliers face sharper questions: not simply whether an ingredient performs, but whether performance is documented in a form a brand can cite under scrutiny from both regulators and retrieval systems.

Who bears the workload?

The burden does not fall evenly. Large multinationals already run the testing infrastructure and legal review that the new environment rewards. Smaller brands face a build-or-buy decision: invest in substantiation programs or risk invisibility and vulnerability as AI intermediates more of the purchase journey.

The report positions this as a defining competitive divide for the coming cycle. Evidence-based claims, once a differentiator among premium clinical brands, are becoming the entry ticket across categories.

What comes next?

The trend line points toward further formalization: expect more brands to publish their substantiation, more suppliers to package ingredient evidence for AI legibility, and claim-review processes to tighten as AI-distributed inaccuracies create reputational exposure. The next data point to watch is whether regulators begin treating AI-surfaced claims as formal marketing claims subject to existing substantiation rules.